DK2301576T3 - Terapeutisk anvendelse af anti-CS1-antistoffer - Google Patents
Terapeutisk anvendelse af anti-CS1-antistofferInfo
- Publication number
- DK2301576T3 DK2301576T3 DK10180748.5T DK10180748T DK2301576T3 DK 2301576 T3 DK2301576 T3 DK 2301576T3 DK 10180748 T DK10180748 T DK 10180748T DK 2301576 T3 DK2301576 T3 DK 2301576T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- therapeutic use
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55762004P | 2004-03-29 | 2004-03-29 | |
US55762204P | 2004-03-29 | 2004-03-29 | |
US55762104P | 2004-03-29 | 2004-03-29 | |
US10/842,011 US20050025763A1 (en) | 2003-05-08 | 2004-05-07 | Therapeutic use of anti-CS1 antibodies |
US10/982,357 US7709610B2 (en) | 2003-05-08 | 2004-11-05 | Therapeutic use of anti-CS1 antibodies |
EP04810631A EP1729803B1 (en) | 2004-03-29 | 2004-11-08 | Therapeutic use of anti-cs1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2301576T3 true DK2301576T3 (da) | 2012-12-10 |
Family
ID=44597272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10180748.5T DK2301576T3 (da) | 2004-03-29 | 2004-11-08 | Terapeutisk anvendelse af anti-CS1-antistoffer |
Country Status (9)
Country | Link |
---|---|
JP (1) | JP4758984B2 (da) |
CY (1) | CY1115003T1 (da) |
DK (1) | DK2301576T3 (da) |
ES (1) | ES2393539T3 (da) |
HK (2) | HK1099699A1 (da) |
HR (1) | HRP20120975T1 (da) |
IL (1) | IL243687A0 (da) |
PT (1) | PT2301576E (da) |
SI (1) | SI2301576T1 (da) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2300034B1 (en) * | 2008-06-02 | 2018-08-08 | Dana-Farber Cancer Institute, Inc. | Pharmaceutical composition for use in treating or preventing multiple myeloma or waldenstrom's macroglobulinemia |
AU2013337247B2 (en) | 2012-11-05 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
WO2015166056A1 (en) * | 2014-05-02 | 2015-11-05 | Cellectis | Cs1 specific multi-chain chimeric antigen receptor |
US20210187118A1 (en) | 2018-05-18 | 2021-06-24 | Daiichi Sankyo Co., Ltd. | Anti-muc1 antibody-drug conjugate |
CN112442126B (zh) * | 2019-09-04 | 2022-07-29 | 杭州济元基因科技有限公司 | 一种抗人cs1抗原的单克隆抗体及其car-t细胞 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2911601A (en) * | 1999-12-23 | 2001-07-03 | Bristol-Myers Squibb Company | Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof |
-
2004
- 2004-11-08 SI SI200431948T patent/SI2301576T1/sl unknown
- 2004-11-08 JP JP2007506135A patent/JP4758984B2/ja active Active
- 2004-11-08 ES ES10180748T patent/ES2393539T3/es active Active
- 2004-11-08 DK DK10180748.5T patent/DK2301576T3/da active
- 2004-11-08 PT PT101807485T patent/PT2301576E/pt unknown
-
2007
- 2007-07-03 HK HK07107070.1A patent/HK1099699A1/xx unknown
-
2011
- 2011-09-23 HK HK11110054.9A patent/HK1155670A1/xx unknown
-
2012
- 2012-11-28 HR HRP20120975TT patent/HRP20120975T1/hr unknown
- 2012-11-30 CY CY20121101174T patent/CY1115003T1/el unknown
-
2016
- 2016-01-19 IL IL243687A patent/IL243687A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2393539T3 (es) | 2012-12-26 |
JP4758984B2 (ja) | 2011-08-31 |
CY1115003T1 (el) | 2016-12-14 |
HK1099699A1 (en) | 2007-08-24 |
IL243687A0 (en) | 2016-04-21 |
HRP20120975T1 (hr) | 2013-01-31 |
HK1155670A1 (en) | 2012-05-25 |
SI2301576T1 (sl) | 2013-02-28 |
JP2007530675A (ja) | 2007-11-01 |
PT2301576E (pt) | 2012-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2016035I1 (el) | Θεραπευτικη χρηση αντισωματων anti-cs1 | |
LTPA2018515I1 (lt) | Antagonistiniai IL-17 antikūnai | |
DK1940465T3 (da) | Ny anvendelse af anti-IL-1beta-antistoffer | |
DK1802579T3 (da) | Derivater af 3-arylaminopyridin | |
DK1778618T3 (da) | Syntese af triethylentetraminer | |
DK1720866T3 (da) | Fremgangsmåde | |
ATE501174T1 (de) | Antikörper gegen madcam | |
DK1587542T3 (da) | Anvendelse af anti-CD100-antistoffer | |
DK1802872T3 (da) | Rörledning | |
ATE465180T1 (de) | Therapeutische anti-igfr1-antikörper- kombinationen | |
NO20071430L (no) | Anti-OX4OL antistoffer | |
DK1992697T3 (da) | Fremstilling af TNFR-Fc | |
DK1708992T3 (da) | Sulfonamidderivater til behandling af sygdomme | |
DE602005012267D1 (de) | N von geräten | |
DK1639010T3 (da) | Terapeutisk surrogatendepunkt for anti-ctla-4-baseret immunterapi af sygdom | |
DK1763520T3 (da) | Anvendelse af trisubstituerede benzopyranoner | |
DK1744781T3 (da) | Behandling af infektionssygdomme | |
EP1789027A4 (en) | Therapeutic Use of Anti- TF Antigen Antibodies | |
DK1812002T3 (da) | Behandling af mastitis | |
NO20043305D0 (no) | Preparation of lodixanol | |
HK1155670A1 (en) | Therapeutic use of anti-cs1 antibodies | |
FR2877833B1 (fr) | Correcteur de lordoses | |
DK1730109T3 (da) | Syntese af pyrrol-2-carbonitriler | |
FI20041385A0 (fi) | Symmetria-akselin määrittäminen | |
FR2878601B1 (fr) | Bague de traversee de cloison |